Knowledge of the Human Papilloma Virus vaccines, and opinions of Gynaecologists on its implementation in Nigeria

Imran O. Morhason-Bello, Olubukola A. Adesina, Babatunde O. Adedokun, Olutosin Awolude, Clement A. Okolo, Christopher O. Aimakhu, Babatunde O. Akinwunmi, Adesina Oladokun, Isaac F. Adewole


The objective of this study was to determine the knowledge and perception of Nigerian Obstetricians and Gynaecologists towards human papilloma virus vaccine use in Nigeria. A cross sectional study was conducted amongst participants that attended the 42nd Society of Gynaecology and Obstetrics of Nigeria. The findings revealed that 44.5% knew the correct HPV vaccine schedule.

Regarding implementation in Nigeria, 87.4% suggested its incorporation into the national immunization program and about a third agreed that it should be a precondition for school enrolment. Regression analysis showed that senior residents were more likely to have adequate knowledge of the vaccine compared to junior residents (AOR 7.181 95% CI OR=1.792 – 28.782). We conclude that the knowledge of eligibility and schedule is poor. It is recommended that adequate information should be provided to this group of health workers because of their strategic position in its implementation in Nigeria (Afr J Reprod Health 2013); 17[2]:150-156).


L'objectif de cette étude était de déterminer la connaissance et la perception des obstétriciens et gynécologues du Nigeria vers l'utilisation du virus du papillome humain  au Nigeria. Une étude transversale a été menée auprès des participants qui ont assisté à la 42e  Conférence de la Société de la Gynécologie et d'Obstétrique du Nigeria. Les résultats ont révélé que 44,5% connaissaient le propre calendrier de vaccination contre le VPH.  En ce qui concerne la mise en œuvre au Nigeria, 87,4% ont suggéré son incorporation dans le programme national de vaccination et environ un tiers étaient d’accord qu'il devrait être une condition préalable à la scolarisation. L'analyse de régression a montré que les habitants  plus âgés  étaient plus susceptibles d'avoir une connaissance suffisante du vaccin par rapport aux jeunes habitants (AOR 7,181 IC 95% OR = 1,792 à 28,782). Nous concluons qu’il y a une mauvaise connaissance de l'admissibilité et le calendrier.   Il est recommandé que des informations adéquates soient fournies à ce groupe de personnel de santé en raison de leur position stratégique dans sa mise en œuvre au Nigeria. (Afr J Reprod Health 2013); 17[2]:150-156).


Keywords: Human papilloma Virus Vaccine, HPV, Knowledge, Perception, Nigeria

Full Text:



Anorlu RI. Cervical cancer: the sub-Saharan African perspective. Reprod Health Matters. 2008; 16(32): 41-

Drain PK, Holmes KK, Hughes JP, Koutsky LA. Determinants of cervical cancer rates in developing countries. Int J Cancer. 2002; 100(2): 199-205.

Adewole IF, Benedet JL, Crain BT, Follen M. Evolving a strategic approach to cervical cancer control in Africa. Gynecol Oncol. 2005; 99(3 Suppl 1): S209-12.

Anorlu RI, Orakwue CO, Oyeneyin L, Abudu OO. Late presentation of patients with cervical cancer to a tertiary hospital in Lagos: what is responsible? Eur J Gynaecol Oncol. 2004; 25(6): 729-32.

Rob U, Rahman M, Bellows B. Evaluation of the impact of the voucher and accreditation approach on improving reproductive behaviors and RH status: Bangladesh. BMC Public Health. 2011; 11: 257.

Bogaards JA, Coupe VM, Xiridou M, Meijer CJ, Wallinga J, Berkhof J. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence. Epidemiology. 2011; 22(4): 505-15.

Beard K. Reducing the rate of cervical cancer: ethical challenges in public health. J Natl Black Nurses Assoc. 2010; 21(2): 39-43.

Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005; 366(9490): 991-8.

Herzog TJ, Huh WK, Downs LS, Smith JS, Monk BJ. Initial lessons learned in HPV vaccination. Gynecol Oncol. 2008; 109(2 Suppl): S4-11.

Herzog TJ, Huh WK, Einstein MH. How does public policy impact cervical screening and vaccination strategies? Gynecol Oncol. 2010; 119(2): 175-80.

Javitt G, Berkowitz D, Gostin LO. Assessing mandatory HPV vaccination: who should call the shots? J Law Med Ethics. 2008; 36(2): 384-95, 214.

Boeke AJ. [Advisory report from the Health Council of the Netherlands to include human papillomavirus vaccination in the national immunisation programme for the prevention of cervical cancer]. Ned Tijdschr Geneeskd. 2008; 152(17): 981-3.

Yamamoto N, Mori R, Jacklin P, Osuga Y, Kawana K, Shibuya K, et al. Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical cancer in Japan: a cost-effectiveness analysis. Bjog. 2011.

Dekker AH. Fostering acceptance of human papillomavirus vaccines. J Am Osteopath Assoc. 2006; 106(3 Suppl 1): S14-8.

Harper DM, Williams KB. Prophylactic HPV vaccines: current knowledge of impact on gynecologic premalignancies. Discov Med. 2010; 10(50): 7-17.

Chan ZC, Chan TS, Lam YM, Lau LM, Li KK, Tam WH. HPV vaccination in Hong Kong: implications f or medical education. Asian Pac J Cancer Prev. 2011; 12(4): 1095-9.

de Carvalho NS, Teixeira LM, Pradel EM, Gabardo J, Joly C, Urbanetz AA. Vaccinating against HPV: physicians' and medical students' point of view. Vaccine. 2009; 27(20): 2637-40.

Dehlendorf C, Levy K, Ruskin R, Steinauer J. Health care providers' knowledge about contraceptive evidence: a barrier to quality family planning care? Contraception. 2010; 81(4): 292-8.

Berlan D, Shiffman J. Holding health providers in developing countries accountable to consumers: a synthesis of relevant scholarship. Health Policy Plan. 2012; 27(4): 271-80.

Shalom MM, Hahn EE, Casillas J, Ganz PA. Do survivorship care plans make a difference? A primary care provider perspective. J Oncol Pract. 2011; 7(5): 314-8.

Subramanian L, Cisek C, Kanlisi N, Pile JM. The Ghana vasectomy initiative: facilitating client-provider communication on no-scalpel vasectomy. Patient Educ Couns. 2010; 81(3): 374-80.

Brown EC, Little P, Leydon GM. Communication challenges of HPV vaccination. Fam Pract. 2010; 27(2): 224-9.

Duval B, Gilca V, McNeil S, Dobson S, Money D, Gemmill IM, et al. Vaccination against human papillomavirus: a baseline survey of Canadian clinicians' knowledge, attitudes and beliefs. Vaccine. 2007; 25(45): 7841-7.

Vadaparampil ST, Kahn JA, Salmon D, Lee JH, Quinn GP, Roetzheim R, et al. Missed clinical opportunities: provider recommendations for HPV vaccination for 11-12 year old girls are limited. Vaccine. 2011; 29(47): 8634-41.

Kahn JA, Cooper HP, Vadaparampil ST, Pence BC, Weinberg AD, LoCoco SJ, et al. Human papillomavirus vaccine recommendations and agreement with mandated human papillomavirus vaccination for 11-to-12-year-old girls: a statewide survey of Texas physicians. Cancer Epidemiol Biomarkers Prev. 2009; 18(8): 2325-32.

Lutringer-Magnin D, Kalecinski J, Barone G, Leocmach Y, Regnier V, Jacquard AC, et al. Human papillomavirus (HPV) vaccination: perception and practice among French general practitioners in the year since licensing. Vaccine. 2011; 29(32): 5322-8.

Hopkins TG, Wood NJ, West RM, Darling JC. UK health professionals' attitudes and knowledge regarding Human Papillomavirus (HPV) vaccination: a West Yorkshire Study. J Paediatr Child Health. 2009; 45(11): 652-5.


  • There are currently no refbacks.